Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01933503 · ClinicalTrials.gov registry record · Phase 1
Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)
A Phase 1 study, sponsored by Intercept Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01933503 is a Phase 1 study that has completed, run by Intercept Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT01933503, a Phase 1 study, has completed, sponsored by Intercept Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single center, open label, randomized, parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of obeticholic acid (OCA).
Interventions
- DRUG OCA 10 mg
- DRUG OCA 25 mg
- DRUG OCA 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01933503
The ClinicalTrials.gov registry entry for NCT01933503 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercept Pharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which OCA 10 mg is the first listed.
NCT01933503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01933503 about?
NCT01933503 is a clinical study titled "Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)". This is a single center, open label, randomized, parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of obeticholic acid (OCA).
What is the current status of trial NCT01933503?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01933503?
The interventions under investigation include: OCA 10 mg (DRUG), OCA 25 mg (DRUG), OCA 5 mg (DRUG).
Who is sponsoring clinical trial NCT01933503?
This trial is sponsored by Intercept Pharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.